Look beyond the healthcare company's recent setbacks.

After a series of unfortunate regulatory rejections and manufacturing issues surfaced, Regeneron’s shares dipped to $483 this ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

(This is an excerpt of the Health Rounds newsletter, where we present latest medical studies on Tuesdays and Thursdays.) By ...

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Regeneron Pharmaceuticals sees its Relative Strength Rating reach the 80-plus level.

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

Regeneron released new early data on two of its blood cancer drugs at ASH, aiming to expand treatment options for patients ...

Dec 6 (Reuters) - Regeneron said on Saturday its experimental cancer combination therapy was effective and showed ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...

The big biotech, which has made genetic medicine a focus in recent years, is paying Tessera $150 million for rights to a ...